Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-09-24
1999-05-11
Knode, Marian C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 2613, A61K31/70
Patent
active
059027940
ABSTRACT:
Site 1- and site 2-selective derivatives of cAMP have been found to inhibit the of a variety of cancer and leukemic cells. The compounds have been found to have a synergistic effect in cancer and leukemic cell growth inhibition when a site 1-selective compounds is used in combination with a site 2-selective compound.
REFERENCES:
patent: 3849397 (1974-11-01), Robins et al.
patent: 3849553 (1974-11-01), Dea et al.
patent: 3856776 (1974-12-01), Cehovic et al.
patent: 3948886 (1976-04-01), Shuman et al.
patent: 4058659 (1977-11-01), Robins et al.
patent: 4208406 (1980-06-01), Lapinet et al.
patent: 4369181 (1983-01-01), Miller et al.
patent: 4861873 (1989-08-01), Robins et al.
patent: 5026836 (1991-06-01), Robins et al.
patent: 5041426 (1991-08-01), Robins et al.
Y. S. Cho-Chung, "Site Selective 8-Chloro-Cyclic Adenosine 3', 5'-Monophosphate as a Biologic Modulator of Cancer: Restoration of Normal Control Mechanisms," J. Nat. Cancer Inst. USA, 81(13), 982-987 (Jul. 5, 1989).
Katsaros et al., "Site-Selective Cyclic AMP Analogs Provide a New Approach Control of Cancer Cell Growth," FEBS Letters, 223(1), 97-103 (Oct., 1987).
Cho-Chung et al.(I), "Site Selective cAMP Analogs are Cytostatic and Differentiating Agents for a Spectrum of Human Cancer Cell Lines: Potential for Application to Chemotherapy," Proc. Am. Soc. Clin. Oncology, 6, Abstr. 62, p. 17, (Mar. 17, 1987).
Cho-Chung et al. (II), "In vivo Inhibition of Growth of Two Hormone-Dependent Mammary Tumors by Dibutyryl Cyclic AMP," Science, 183, 87-88 (Jan. 11, 1974).
Tagliaferri et al.(I), "Reverse Transformation of Harvey Murine Sarcoma Virus-transformed NIH/3T3 Cells by Site-Selective Cyclic AMP Analogs," J. Biol. Chem., 263(1), 409-416 (Jan. 5, 1988).
Tagliaferri et al.(II), "Synergistic Inhibition of Growth of Breast and Colon Human Cancer Cell Lines by Site-Selective Cyclic AMP Analogues," Cancer Res., 48, 1642-1650 (Mar. 15, 1988).
Tortora et al., "Site-Selective cAMP Analogs at Micromolar Concentrations Induce Growth Arrest and Differentiation of Acute Promyelocytic, Chronic Myelocytic, and Acute Lymphocytic Human Leukemia Cell Lines," Blood, 71(1), 230-233 (Jan., 1988).
Niles et al., "Regulation of Phosphatidylcholine Metabolism By Cyclic AMP in a Model Alveolar Type 2 Cell Line," J. Biol. Chem., 254(11), 4324-4326 (Jun. 10, 1979).
Miller et al., "Synthesis and Enzymatic and Inotropic Activity of Some New 8-Substituted and 6,8-Disubstituted Derivatives of Adenosine Cyclic 3', 5'-Monophosphate," J. Med. Chem., 23(3), 242-251 (1980).
Mineyama et al., "Synthesis and Biological Activity of 8-Haloadenosine 3', 5'-Cyclic Phosphates," J. Carbohydrates Nucleosides Nucleotides, 1(1), 55-60 (1974).
Tsuji et al., "Neuronal Differentiation of Oat Cell Carcinoma In Vitro by Dibutyryl Cyclic Adenosine 3',5'-Monophosphate," Cancer Letters, 1, 311-318 (1976).
Helson et al., "A Rationale for the Treatment of Metastatic Neuroblastoma," J. Nat. Cancer Inst. USA, 57(3), 727-729 (Sep., 1976).
Holmgren et al., "In Vivo Modulation of Intracellular cAMP and Cell Growth of a Lymphatic Tumour in Mice by Cholera Toxin," Experimental Cell Res., 108, 31-39 (1977).
Prasad, "Differentiation of Neuroblastoma Cells in Culture," Biology Rev., 50, 129-165 (1975).
Rannels et al., "Two Different Intrachain cAMP Binding Sites of cAMP-dependent Protein Kinases," J. Biol. Chem., 255(15), 7085-7088 (Aug. 10, 1980).
Ogreid et al., "Activation of Protein Kinase Isozymes by Cyclic Nucleoside Analogs Used Singly or in Combination," Eur. J. Biochem, 150, 219-227 (1985).
Robinson-Steiner et al., "Probable Involvement of Both Intrachain cAMP Binding Sites in Activation of Protein Kinase," J. Biol. Chem., 258(2), 1032-1040 (Jan. 25, 1983).
T. Beardsley, "Trends in Cancer Epidemiology--A War Not Won," Scientific American, 270(1), 130-138 (Jan., 1994).
Tortora et al., "Phase I Clinical Study with 8-Chloro-cAMP and Evaluation of Immunological Effects in Cancer Patients," Clinical Cancer Research, 1, 377-384 (Apr., 1995).
Crane L. Eric
Knode Marian C.
The United States of America as represented by the Secretary of
LandOfFree
8-CI cAMP as anti-cancer drug does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8-CI cAMP as anti-cancer drug, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8-CI cAMP as anti-cancer drug will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-245689